Published in Cancer Weekly, October 11th, 2005
Elacyt is Clavis Pharma's most advanced drug candidate in development for solid tumors and leukemia. The company has successfully finalized a phase I study in Europe where the product's safety profile was established and clinical benefit (defined as tumor response or stable disease) was reported in 41% of the patients, all suffering from advanced-stage solid...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.